1. www.iwgdf.org
2. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2004;20 Suppl 1:S68-77.
3. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, and Tan JS. Diagnosis and Treatment of Diabetic Foot Infections. Clinical Infectious Diseases 2004;39:885-910
4. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, and Tan JS. Diagnosis and Treatment of Diabetic Foot Infections. J Am Podiatr Med Assoc. 2005;95:183-210.
5. Schaper NC, Apelqvist J, Bakker K. The international consensus and practical guidelines on the management and prevention of the diabetic foot. Curr Diab Rep 2003;3(6):475-479.
6. LeFrock JL, Blais F, Schell RD, et. al.: Cefotoxin in the treatment of diabetic patients with lower extremity infections. Infect Surg 2:361-374, 1983.
7. Lipsky BA, Pecoraro RE, Larson SA, et.al. Outpatient management of uncomplicated lower extremity infections in diabetic patients. Arch Intern Med 1990; 150:790-7
8. Cunha BA. Antibiotic selections for diabetic foot infection: a review. J Foot Ankle Surg 2000;39(4):253-257.
9. West NJ. Systemic antimicrobial treatment of foot infections in diabetic patients. Am J Health System Pharm 1995;52(11):1199-1207.
10. Senneville E. Antimicrobial interventions for the management of diabetic foot infections. Expert Opin Pharmacother 2005;6(2):263-273.
11. Lavery LA, Walker SC, Harkless LB, Felder-Johnson K. Infected puncture wounds in diabetic and non-diabetic adults. Diabetes Care 1995;18(12):1588-1591.
12. Gesser R, McCarroll K, Woods G. Efficacy of ertapenem for treatment of diabetic lower extremity infections: results of comparative trial versus piperacillin/tazobactam. Abstracts of the 41st Annual Meeting of the IDSA 2003; Abstract 321:88.
13. Teppler H, McCarroll K, Gesser RM, Woods GL. Surgical infections with Enterococcus: outcome in patients treated with ertapenem versus piperacillin/tazobactam. Surg Infect (Larchmt) 2002 Winter;3(4):337-349.
14. Citron DM, Goldstein EJ. Discordance in susceptibility testing between doxycycline and tetracycline for Streptococcus pneumoniae. IDSA Abstract 458, 2004.
15. Slater RA, et. al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabetic Medicine 21, 705–709, 2004
16. Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA. 1978;239:2772-2775.
17. Zhanel GG, et. al. Ertapenem: review of a new carbapenem. Expert Rev Anti Infect Ther. 2005 Feb;3(1):23-29.
18. Tice A. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2004 Jun;53 Suppl 2:1183-86.
19. Lipsky BA, Armstrong D, Citron D, et. al. The SIDESTEP study of diabetic foot infections. IDSA Abstract 3776, 2004.
20. Lipsky B, Armstrong D, Citron D, Erb T, King T, Morgenstern D, Rawlins S, Abramson M. Efficacy and safety of ertapenem compared with piperacillin/tazobactam for diabetic foot infections: The SIDESTEP Study. European Congress of Clinical Microbiology and Infectious Diseases Abstract O-407, 2005.
21. Lipsky BA, Armstrong DG, Morgenstern DE, King TR, Abramson MA. The diabetic foot: treating infection and relieving pressure - Does a diabetic foot infection (DFI) wound score correlate with the clinical response to antibiotic treatment? Data from the SIDESTEP study. Diabetic Foot Study Group meeting of the EADS, Thessaloniki, Greece, Sept. 9, 2005. Abstract PS-89, 2005.
22. Lipsky BA, Armstrong DG, Morgenstern DE, King TR, Abramson MA. The SIDESTEP Study of Diabetic Foot Infections (DFI): a multicenter, double-blinded, randomized, controlled trial (RCT) of ertapenem (E) vs. piperacillin/tazobactam (P/T). Diabetic Foot Study Group Abstract O-19, 2005.
23. Lipsky BA, Armstrong DG, Morgenstern DE, King TR, Abramson MA. Does a diabetic foot infection (DFI) wound score correlate with the clinical response to antibiotic treatment? Data from the SIDESTEP Study. Diabetic Foot Study Group Abstract O-21, 2005.
24. Grim SA, Rap RP, Martin CA, et. al. Trimethoprim/sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005 Feb;25(2):253-264.
25. Ruhe J, Monson T, Bradsher R, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: Case Series and Review of the Literature. Clin Infect Dis 40:1429-1434, 2005
26. Fridkin S, et. al. Methicillin-resistant Staphylococcus aureus disease in three communities. NEJM 352:1436-1444.
27. Finberg BW, Boellering RC, Tally FP, et. al. The importance of bactericidal drugs: future directions in infectious diseases. Clin Infect Dis 39:114-120, 2004.
28. Pankey GA, Sabbath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram positive bacterial infections. Clin Infect Dis 38:864-870, 2004.
29. Gillespie EL, Kuti, JL, Nicolau DP, et. al. When “S” does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection. Conn Med 2005 Apr; 69(4):203-210.
30. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid vs. ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004 Jan 1;38(1):17-24.
31. Stevens DL, Dotter B, Madras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004 Feb; 2(1):51-59.
32. Nebaker JR, Hoffman JM, Weir CR, et. al. Arch Intern Med 2005 May 23;165(10):1111-1116.
33. Horsky J, Kuperman GL, Patel VJ. Comprehensive analysis of a medication dosing error related to CPOE. Inform Assoc 2005 Jul-Aug; 12(4):377-382.
34. Patterson ES, Rogers ML, Render ML. Fifteen best practice recommendations for bar-code medication administration in the Veterans Health Administration. Jt Comm J Qual Saf 2004 Jul; 30(7):355-365.
35. Johnson CL, Carlson RA, Tucker CL, et. al. Using BCMA software to improve patient safety in Veterans Administration Medical Centers. J Healthc Inf Manag 2002 Winter; 16(1):46-51.
36. Lipsky BA, et. al. The SIDESTEP study of diabetic foot infections: a multicenter, double-blinded, randomized, controlled trial (RCT) of ertapenem vs. piperacillin/tazobactam. 44th ICAAC meeting, Washington, DC, Oct. 30, 2004. Abstract L-992a.
37. Armstrong DG, Lipsky BA, et. al. Utility of dermal thermometry (DT) as an indicator of clinical cure in diabetic foot infection (DFI): a SIDESTEP substudy. Diabetic Foot Study Group meeting of the EADS, Thessaloniki, Greece, Sept. 9, 2005. Abstract OP1.
38. Sheehan P, Lipsky BA, Armstrong DG, Polis A, Morgenstern D, Dobbins T, Abramson MA. Utility of baseline clinical findings for the prediction of poor outcomes of diabetic foot infections (DFI): from the SIDESTEP study content area. IDSA meeting, San Francisco, October 2005. Abstract 354.
39. Citron DM, Goldstein EJC, Lipsky BA, Tice A, Morgenstern DE, Abramson MA. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from intra-abdominal (IA) versus diabetic foot infections. ICAAC meeting, Washington, DC, December 2005. |
